Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine in ESP Block for Lumbar Spinal Fusion
NCT05417113Phase 4Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Postoperative Intravenous Opioid Consumption at 72 hours. Started Aug 2022; status: terminated.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05417113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417113.